For example, in high-grade serous ovarian carcinoma, BRCA mutations and TP53 alterations are powerful prognostic and therapeutic determinants, especially when considering drugs such as PARP inhibitors. The gene discussed is TP53; the disease is ovarian serous carcinoma.